Skip to main navigation Skip to search Skip to main content

Antitumor effect of salidroside on mice bearing HepA hepatocellular carcinoma

  • Hanjun Song
  • , Jianjie Wang
  • , Molin Wang
  • , Hang Dong
  • , Lijiang Li
  • , Tengyuan Zhang
  • , Shaobo Zhou

Research output: Contribution to journalArticlepeer-review

2 Citations (Scopus)
2 Downloads (Pure)

Abstract

Salidroside, a phenylpropanoid glycoside extracted from Rhodiola rosea L., has antiproliferative effects on tumour cells in mice. However it’s antitumor mechanism remains largely unknown. In this study, 4 groups of mice bearing hepatocarcinoma cells were given treatment with vehicle alone, cyclophosphamide (25 mg/kg, i.p.) and salidroside, either 100 or 200 mg/kg (p.o.) for 14 days. The morphology of tumour specimens was analysed by transmission electron microscopy. Apoptotic cells in sections of mouse tumour tissue were analysed using an in situ apoptosis kit. The expression of Bcl-2, Bax and caspase 3 mRNA were examined with RT-PCR. The results showed that the tumour weights in groups 100 or 200 mg/kg/day of salidroside were reduced significantly (45.34 and 52.48% respectively), compared to vehicle groups. Salidroside increased apoptotic cells index, e.g. in 200 mg/kg group, it was four times higher compared to the control group. Even more, treatment with salidroside decreased Bcl-2 mRNA expression and increased Bax and caspase 3 mRNA expressions. These indicated that the antitumor mechanism of salidroside may induce tumour cell apoptosis in mice by triggering the mitochondrial-dependent pathway and activation of caspase 3.
Original languageEnglish
JournalActa Farmaceutica Bonaerense
Volume34
Issue number10
Publication statusPublished - 5 Aug 2015

Keywords

  • Antitumor Effect of Salidroside
  • Nutrition and Metabolism

Fingerprint

Dive into the research topics of 'Antitumor effect of salidroside on mice bearing HepA hepatocellular carcinoma'. Together they form a unique fingerprint.

Cite this